Get Healthy!
Results for search "Weight Loss".
Health Videos - 7
Health News Results - 206
TUESDAY, May 13, 2025 (HealthDay News) — Cutting-edge weight-loss drugs like Ozempic/Wegovy can cut alcohol intake dramatically in a short amount of time, a new study says.
People taking semaglutide or liraglutide reduced their alcohol consumpt...
- Dennis Thompson HealthDay Reporter
- |
- May 13, 2025
- |
- Full Page
MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.
The study — published May 11 in the
FRIDAY, April 18, 2025 (HealthDay News) — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies.
Eli Lilly said its experimental drug, orforglipron, helped people with ...
- I. Edwards HealthDay Reporter
- |
- April 18, 2025
- |
- Full Page
TUESDAY, April 15, 2025 (HealthDay News) — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.
The company said the injury went away after the person stopped taking the drug, called danuglipron, The Associated Press reported.
The pill was in early testing to help determine the bes...
- I. Edwards HealthDay Reporter
- |
- April 15, 2025
- |
- Full Page
The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden administration initiative that could have helped millions of Americans access the medications.
Catherine Howden, a spokeswoman for the Centers for Medicare and Medicaid Services (CMS), said that expanding coverage fo...
- I. Edwards HealthDay Reporter
- |
- April 7, 2025
- |
- Full Page
Fasting every other day can prompt more weight loss than simply cutting calories, a new clinical trial shows.
People who undertook 4:3 intermittent fasting lost just under 8% of their body weight within a year, compared to a 5% loss among people who cut their daily calories by about a third, researchers reported March 31 in the
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24.
The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co.
- I. Edwards HealthDay Reporter
- |
- March 25, 2025
- |
- Full Page
The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Novo Nordisk, the Danish company behind Wegovy, announced Wednesday that it has lowered its monthly cost by 23%. The new price -- $499 per month -- takes effect immediately. ...
- I. Edwards HealthDay Reporter
- |
- March 7, 2025
- |
- Full Page
GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has concluded.
Earlier research had potentially linked these drugs -- which are used to treat type 2 diabetes and obesity -- with suicidal thoughts and self-harm, researchers add...
- Dennis Thompson HealthDay Reporter
- |
- February 28, 2025
- |
- Full Page
MONDAY, Feb. 24, 2025 (HealthDay news) -- Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, a new study suggests.
People with new knees and hips are significantly less likely to need follow-up surgery to fix wear and tear on their artificial joint if they lose weight using
Juice cleanses are a popular way to kickstart a health journey, but these diets may do more harm than good in as little as three days.
A study published recently in the journal Nutrients found that consuming vegetable and fruit juice-only diets for three days triggered detrimental gut and oral bacteria changes linked to inflam...
- Denise Mann HealthDay Reporter
- |
- February 18, 2025
- |
- Full Page
Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their intake.
The research found that, compared to placebo, weekly injections of semaglutide (also marketed for weight loss as Wegovy) helped reduce cravings in people with alcohol use disorders. The drug also seemed to reduce t...
- Ernie Mundell HealthDay Reporter
- |
- February 12, 2025
- |
- Full Page
“Yo-yo” dieting -- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people with type 1 diabetes, a new study warns.
Diabetics with greater weight fluctuations experienced a 40% decline in their kidneys’ ability to filter toxins from th...
- Dennis Thompson HealthDay Reporter
- |
- February 5, 2025
- |
- Full Page
Weight-loss surgery can protect the liver health of patients with obesity and fatty liver disease, a new study reports.
Patients had a 72% lower risk of developing serious complications of liver disease after undergoing weight-loss surgery, researchers reported in Jan. 27 in the journal Nature Medicine.
They a...
- Dennis Thompson HealthDay Reporter
- |
- January 30, 2025
- |
- Full Page
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia.
But these drugs also come with risks that shouldn't be overlooked, researchers warn ...
- India Edwards HealthDay Reporter
- |
- January 21, 2025
- |
- Full Page
Black people with obesity are less likely to get weight-loss surgery than others.
Black people are just as likely to discuss the procedure with their doctor -- nearly 10%, compared with 9% of patients of other races, researchers said.
But only about 8% of those Black patients go on and actually get the surgery, compared with nearly 13% of other patients, researchers report in a stud...
- Dennis Thompson HealthDay Reporter
- |
- January 21, 2025
- |
- Full Page
The way obesity is diagnosed needs to become more sophisticated, an international commission has concluded.
Using body-mass index (BMI) to tell who is overweight or obese is not reliable, and can result in misdiagnosis, the Commission on Clinical Obesity says in a new paper published today in The Lancet Diabetes & En...
- Dennis Thompson HealthDay Reporter
- |
- January 14, 2025
- |
- Full Page
When it comes to living a longer life, staying active may matter far more than what the scale says.
Per the largest study yet on fitness, body weight, and longevity published recently in the British Journal of Sports Medicine, researchers found that people who are aerobically fit (i.e.,...
- India Edwards HealthDay Reporter
- |
- January 9, 2025
- |
- Full Page
A new diet is on the New Year’s resolution list for nearly half of U.S. adults, according to a new survey from the Physicians Committee for Responsible Medicine.
However, many plan to pick up diets with dicey track records, survey results show.
About 46% of adults said they plan to start a new diet in 2025, the survey found.
When asked which diets they plan to try, resul...
- Dennis Thompson HealthDay Reporter
- |
- January 6, 2025
- |
- Full Page
Wondering which popular diet will help you shed extra weight in a healthy way this year?
The Mediterranean diet tops the best diet categories in the U.S. News & World Report 2025 edition.
According to the report, the eating style that refers to the traditional eating habits of the people who live in the countries that border the Mediterranean Sea, is the most highly-rated diet a...
- Denise Maher HealthDay Reporter
- |
- January 3, 2025
- |
- Full Page
THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes.
Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weig...
- Denise Maher HealthDay Reporter
- |
- December 26, 2024
- |
- Full Page
The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss meds, a new study finds.
Data on almost 17 million adults nationwide showed the obesity rate -- which has been rising for years -- fell from 46.2% of adults in 2021 to 45.6% in 2023,...
- Ernie Mundell HealthDay Reporter
- |
- December 13, 2024
- |
- Full Page
The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs' cost should be covered by Medicare, Medicaid and private insurers.
Late last month, the Biden administration
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
"Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice," Dr. Leonard G...
- Robin Foster HealthDay Reporter
- |
- December 4, 2024
- |
- Full Page
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.
However, the move would have to be approved by the new Trump administration.
Right now, a law passed b...
- Ernie Mundell HealthDay Reporter
- |
- November 26, 2024
- |
- Full Page
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm.
In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs in people with or without diabetes.
GLP-1s include blockbuster diabetes medicines such as Ozempic and it...
- Ernie Mundell HealthDay Reporter
- |
- November 26, 2024
- |
- Full Page
So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where decadent food will be served in abundance.
Luckily, one expert from Baylor College of Medicine has tips on how to enjoy holiday fare while on these medications, without overdoing it.
GLP-1 medications, which include <...
- Robin Foster HealthDay Reporter
- |
- November 23, 2024
- |
- Full Page
The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says.
GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like
It may seem counter-intuitive, but losing weight without even trying may not be a good thing.
"It's not typical to have a noticeable drop in weight without changing how much you're eating, being more physically active or trying to lose weight," said dietitian Christine Goukasian.
"Unexplained weight loss is a red...
- Carole Tanzer Miller HealthDay Reporter
- |
- November 9, 2024
- |
- Full Page
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.
“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO
Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.
Under the Medicaid system, individual states are allowed to decide whether to cover GLP-1 drugs, which inclu...
- Dennis Thompson HealthDay Reporter
- |
- November 5, 2024
- |
- Full Page
The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found.
People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy -- had a nearly 14% decrease in their body weight after 68 weeks, compared with 3% of people given a placebo, results showed. The trial was fun...
- Dennis Thompson HealthDay Reporter
- |
- November 1, 2024
- |
- Full Page
The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows.
Patients taking semaglutide -- the active agent in Ozempic and Wegovy -- had as much as a 52% reduction in kidney damage, as measured by urine testing, researchers reported Oct. 25 in the journal ...
- Dennis Thompson HealthDay Reporter
- |
- October 28, 2024
- |
- Full Page
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.
Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new tally finds.
"In contrast, there was a 25.6% decrease in patients undergoing metabolic bariatric surg...
- Ernie Mundell HealthDay Reporter
- |
- October 25, 2024
- |
- Full Page
Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says.
People with type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer’s compared to patients taking seven other diabetes drugs, researchers reported...
- Dennis Thompson HealthDay Reporter
- |
- October 24, 2024
- |
- Full Page
Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 deaths a year in the United States, a new study claims.
Obesity and all its attendant ills -- type 2 diabetes, heart disease an...
- Dennis Thompson HealthDay Reporter
- |
- October 24, 2024
- |
- Full Page
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.
What prompted the FDA to reconsider its
As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts.
But a new study involving more than 54,000 U.S. adolescents found no such link.
In fact, obese kids who used the drugs had a 33% decline in their risk for thoughts of suicide and suicide...
- HealthDay Reporter
- |
- October 14, 2024
- |
- Full Page
Results from a very small study suggest that a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could help erase the need for insulin in folks with type 2 diabetes.
The new trial hasn't yet been published in a peer-reviewed journal and it included only 14 patients.
However, Dutch researchers report that after six months of the combo therapy, 12 o...
- Ernie Mundell HealthDay Reporter
- |
- October 14, 2024
- |
- Full Page
The key to weight loss could come down to a combination of 14 “skinny genes,” a recent study says.
People with these genes dropped twice as much weight through regular exercise compared to those without the genes, researchers found.
Those with the most of these genetic markers lost up to 11 pounds following eight weeks of
When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance plans, a new survey shows.
In a report published Wednesday in the journal Health Affairs, researchers also found that a third of compani...
- Robin Foster HealthDay Reporter
- |
- October 9, 2024
- |
- Full Page
Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy.
Now, research finds this scenario is more likely if the patient is taking popular new weight-loss meds such as Ozempic
- Ernie Mundell HealthDay Reporter
- |
- October 1, 2024
- |
- Full Page
In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people’s risk of opioid overdose.
People with type 2 diabetes prescribed semaglutide (Ozempic, Wegovy) had a significantly lower risk of an opioid OD t...
- Dennis Thompson HealthDay Reporter
- |
- September 25, 2024
- |
- Full Page
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
While testifying before the Senate Committee on Health, Education, Labor and Pens...
- Robin Foster HealthDay Reporter
- |
- September 25, 2024
- |
- Full Page
Heavy-duty endurance exercise can cause body fat levels to drop without any accompanying weight loss, a new small-scale study indicates.
A group of eleven middle-aged men who cycled 710 miles in seven days lost only about 1% of their total weight, because they ate and drank enough to offset the calorie burn.
But they lost over 9% of their overall body fat, including a nearly 15% red...
- Dennis Thompson HealthDay Reporter
- |
- September 20, 2024
- |
- Full Page
Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days.
They’re in short supply, and often too expensive to afford without insurance coverage.
Because of these barriers, many people are doing an end-run around their doctor’s office, reaching out ...
- Dennis Thompson HealthDay Reporter
- |
- September 18, 2024
- |
- Full Page
Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that.
In a new decades-long study, veterans with diabetes and what's known as metabolic dysfunction-associated steatotic liver disease (MASLD) were 14% less likely to progress t...
- Ernie Mundell HealthDay Reporter
- |
- September 16, 2024
- |
- Full Page
Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone associated with blood sugar and appetite, a new study finds.
Ozempic and Wegovy (semaglutide) promoted the loss of 10% or more body weight in 61% of people being treated for o...
- Dennis Thompson HealthDay Reporter
- |
- September 13, 2024
- |
- Full Page